Secretion of tissue plasminogen activator and plasminogen activator inhibitor 1 during cardiopulmonary bypass

被引:31
作者
Chandler, WL [1 ]
Velan, T [1 ]
机构
[1] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
关键词
cardiopulmonary bypass; tissue plasminogen activator; plasminogen activator inhibitor; computer modeling;
D O I
10.1016/j.thromres.2003.11.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Cardiopulmonary bypass (CPB) is associated with elevated tissue plasminogen activator (t-PA) levels during CPB and increased plasminogen activator inhibitor 1 (PAI-1) levels post-operatively. The goal of this study was to estimate the rate of t-PA and PAI-1 secretion in vivo, before, during and after CPB. Materials and methods: Estimated rates of t-PA and PAI-1 secretion were based on measured levels of active and total t-PA, and active and total PAI-1, obtained before, during and after CPB from nine males, combined with a computer model of each patient's vascular system that continuously accounted for secretion, clearance, hemodilution, blood loss and transfusion. Results and conclusions: At baseline, the average t-PA and PAI-1 secretion rates were 0.74 +/- 0.33 and 1.28 +/- 0.74 pmol/s, respectively. Within 5 min of CPB initiation, t-PA secretion increased six-fold to 4.41 +/- 2.58 pmol/s, while PAI-1 secretion was unchanged, resulting in a six-fold increase in active t-PA levels. t-PA secretion remained elevated throughout CPB and into the early post-operative period. Average PAI-1 secretion did not start to increase until the end of CPB. By 2 It after surgery, average PAI-1 secretion had increased 15-fold to 19.60 +/- 17.10 pmol/s, resulting in reduced levels of active t-PA even though t-PA secretion was still elevated. We conclude that CPB induces an immediate sustained increase in t-PA secretion followed by a delayed progressive increase in PAI-1 production. Variations in the level of active t-PA are a function of the relative rates of t-PA versus PAI-1 secretion at different times during and after surgery. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:185 / 192
页数:8
相关论文
共 50 条
[31]   Role of plasminogen activator inhibitor-1 polymorphism on the development of vasoplegic syndrome associated with cardiopulmonary bypass [J].
J Jimenez ;
J Iribarren ;
M Brouard ;
Y Barrios ;
J Raya ;
L Lorente ;
R Perez ;
C Garcia ;
J Martinez ;
R Martinez ;
M Mora .
Critical Care, 11 (Suppl 2)
[32]   Expression and regulation of plasminogen activator and plasminogen activator inhibitor type-1 in rat epididymis [J].
ZHOU Hongming ZHANG Tong and LIU YixunState Key Laboratory of Reproductive Biology Institute of Zoology Chinese Academy of Sciences Beijing China .
Chinese Science Bulletin, 1997, (09) :779-783
[33]   Expression and regulation of plasminogen activator and plasminogen activator inhibitor type-1 in rat epididymis [J].
Zhou, HM ;
Zhang, T ;
Liu, YX .
CHINESE SCIENCE BULLETIN, 1997, 42 (09) :779-783
[34]   Regulation of expression of tissue plasminogen activator and plasminogen activator inhibitor-1 by dichloroacetic acid in human fibroblasts from normal peritoneum and adhesions [J].
Diamond, MP ;
El-Hammady, E ;
Wang, R ;
Kruger, M ;
Saed, G .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 190 (04) :926-933
[35]   Glycation does not alter LDL-induced secretion of tissue plasminogen activator and plasminogen activator inhibitor-1 from human aortic endothelial cells [J].
Klein, RL ;
Semler, AJ ;
Baynes, JW ;
Thorpe, SR ;
Lyons, TJ ;
Jenkins, AJ .
MAILLARD REACTION: CHEMISTRY AT THE INTERFACE OF NUTRITION, AGING, AND DISEASE, 2005, 1043 :379-389
[36]   HPLC analysis of plasminogen and tissue plasminogen activator [J].
Baranowski, J ;
Zydrón, M ;
Baranowska, I ;
Glinska, A .
CHEMIA ANALITYCZNA, 2003, 48 (03) :621-626
[37]   Tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in patients with symptomatic lower extremity artery disease [J].
Wieczor, Radoslaw ;
Wieczor, Anna Maria ;
Rosc, Danuta .
MINERVA CARDIOLOGY AND ANGIOLOGY, 2021, 69 (02) :161-171
[38]   Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behcet's disease [J].
Ozoran, K ;
Duzgun, N ;
Gurler, A ;
Tutkak, H ;
Tokgoz, G .
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1995, 24 (06) :376-382
[39]   Plasminogen activator inhibitor-1 and tissue-type plasminogen activator are up-regulated during unilateral ureteral obstruction in adult rats [J].
Ishidoya, S ;
Ogata, Y ;
Fukuzaki, A ;
Kaneto, H ;
Takeda, A ;
Orikasa, S .
JOURNAL OF UROLOGY, 2002, 167 (03) :1503-1507
[40]   THE VASCULAR PLASMINOGEN-ACTIVATOR AS SOURCE OF THE FIBRINOLYTIC POTENTIAL OBSERVED DURING CARDIOPULMONARY BYPASS [J].
BANOS, G ;
DELAPENA, A ;
IZAGUIRRE, R .
THROMBOSIS RESEARCH, 1992, 67 (05) :579-588